The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations by Cyrus Huneycutt | Dec 16, 2023 | 0 comments Submit a Comment Cancel replyYou must be logged in to post a comment.
Recent Comments